family / friend
MDS and Agent Orange with Dr. David Steensma
Advancing Research Through the Global PNH Registry: Q & A with Dr. David J. Araten
The is a pre-recorded session with the original PNH Registry Launch video and audience Q & A.
Living with PNH: A Patient Panel Discussion
Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH
May 25, 2021
Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant
Key Points
Donor-derived T cells with native specificity for multiple myeloid leukemia antigens can be expanded ex vivo.
Infusion of mLSTs after HCT is well tolerated and produces antileukemia effects.
Researchers Uncover How MN1 Overexpression Causes AML
Venetoclax
Venetoclax is used to treat chronic lymphocytic leukemia or small lymphocytic leukemia in adults. Venetoclax is used alone or in combination with other cancer medicines to treat these conditions.
RARA Agonist Plus Azacitidine Shows Encouraging Activity in Relapsed/Refractory AML
The novel agentSY-1425 combined with azacitidine appears to be active in retinoic acid receptor alpha (RARA) superenhancer–positive newly diagnosed and relapsed or refractory
Haploidentical Transplant for MDS
Dr. Shaffer provides an overview of the haploidentical transplant process and discusses how this treatment option might be right for some MDS patients.